Join our daily newsletter At The Bell to receive exclusive market insights
- Avecho Biotechnology (AVE) sees positive results from its Phase IIa Study of its CBD formulation on patients with osteoarthritis (OA)
- The study investigated the effects of a topical CBD gel on OA of the hand with 15 patients recruited to apply Avecho’s TPM formulation daily to the affected joints
- The primary aim of the study was to measure the change in daily hand pain while the secondary aim included improving hand functionality
- Over the four weeks, daily improvements were encountered in hand pain, hand functionality, grip strength, stiffness and anxiety
- Avecho is up 7.69 per cent on the market with shares trading at 1.4 cents
Avecho Biotechnology (AVE) has recorded positive results from its Phase IIa Study of its CBD formulation on patients with osteoarthritis (OA).
The study investigated the effects of a topical CBD gel on OA of the hand, affecting the fingers and thumb.
A total of 15 patients applied Avecho’s TPM formulation daily to the affected joints on their hand.
The study ran for six weeks which includes one week of baseline measurements, four weeks of treatment and one week of washout after dosing.
The primary aim of the study was to measure the change in daily hand pain while the secondary aim included improving hand functionality.
Over the four weeks, daily improvements were encountered in hand pain, hand functionality, grip strength, stiffness and anxiety.
“We have already received commercial interest in a topical CBD formulation and are confident the data from this study will be of interest to potential licensees,” CEO Dr Paul Gavin said.
“The addition of topical cannabinoid products to our cannabinoid portfolio would be of immense value, not just for pain indications, but also in fields like dermatology.”
The study was run by Principal Investigator Dr Daniel Lewis from the Daniel Lewis Rheumatology Centre and Co-Investigator Professor Iain McGregor from the Lambert Initiative.
“We are very encouraged by these results which will need to be confirmed with a longer placebo-controlled trial in a larger number of patients in due course,” Dr Lewis stated.
“If further trials replicate the benefits seen in this initial trial then we believe this topical therapy will become a cornerstone therapy for the management of hand osteoarthritis.”
Avecho was up 7.69 per cent on the market and were trading at 1.4 cents at 12:17 pm AEDT.
